Navigation Links
Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
Date:10/1/2010

PASADENA, Calif., Oct. 1 /PRNewswire/ -- Maven Biotechnologies today announced that the company has been awarded $1.96 million by the National Institute for Allergy and Infectious Disease (NIAID), part of the NIH, to support the commercialization of their LFIRETM imaging technology for label-free protein microarrays and cell-based assays. The highly competitive grant was awarded to Maven through the federal stimulus package initiative for Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN).

(Logo: http://photos.prnewswire.com/prnh/20101001/LA75512LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101001/LA75512LOGO)

"Maven welcomes the support of the NIH to bring our platform to market," says Chief Technology Officer David Ralin. "LFIRETM's label-free, multiplexed capabilities and inherent simplicity will directly benefit our customers, delivering better results in less time and with lower costs." Target applications for the technology include - but are not limited to - immunoassays in the research and diagnostics markets, cell-based studies, high-throughput pharmaceuticals screening and the established label-free applications in biomolecular interaction analysis.

Chief Engineering Officer Jeffrey Chongsathien M.A. Cantab. adds, "We look forward to creating a robust, flexible and modular product portfolio of laboratory instrumentation and consumables, built on LFIRETM." The initial instrument will be a desktop microplate reader, with a set of 'alpha' evaluation units expected to be completed in the first quarter of 2011 and made available for use by key academic collaborators and strategic industry partners.

Company Founder and CEO William Rassman M.D. noted that the grant will 'jump-start' the commercializat
'/>"/>

SOURCE Maven Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
6. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
7. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
11. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Blueprint Medicines (NASDAQ: BPMC ) today ... of 9,367,708 shares of common stock at a ... shares of common stock issued upon the full ... purchase additional shares. The gross proceeds from the ... $168.6 million, before underwriting discounts and estimated offering expenses. ...
(Date:5/5/2015)... May 05, 2015 VetStem Biopharma, ... Animal Health, Jeffrey Schaffer, DVM, as Director of ... 15 years of experience in the veterinary regenerative ... addition to our veterinarian lead organization”. Dr. ... “Dr. Schaffer will be responsible for all technical ...
(Date:5/5/2015)... May 5, 2015  Tikcro Technologies Ltd. (OTCQB: ... to continue trading on OTCQB  Marketplace, the market ... Marketplace allows for a continuous public market for ... have real-time quotes and market information on us ... OTCQB Marketplace includes U.S. and international companies in ...
(Date:5/5/2015)... 5, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... , President and Chief Executive Officer, will present ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ... > click the red "register/ watch presentations" button ... online event where investors are invited to ask ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... ... Technology for In Situ Monitoring and Control of Complex Particle and Droplet Systems, which ... situ and in real time. , ... (PRWEB) March 10, 2010 -- When is turbidity not enough? For ...
... ... , ... ... , ...
... ... ... ... ...
Cached Biology Technology:Beyond Turbidity: Selecting Appropriate Technology for in Situ Monitoring and Control of Complex Particle and Droplet Systems 2IGEN Networks engages new auditors and converts debt 2A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 2A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 3A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 4A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 5A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 6A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 7A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 8
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... used by a species of tropical seaweed to ward ... humans. The compounds are part of a unique chemical ... and that may provide a wealth of potential new ... at the Georgia Institute of Technology found that the ...
... note in the symphony of good news that usually ... promise in regenerative medicine, thanks to their ability to ... possible to markedly improve the effectiveness of many medical ... grafts for treating burn victims, and the treatment of ...
... of the parasitic worm that causes trichinosis, a disease ... wild game animals, such as bear and walrus. ... of Medicine in St. Louis and their collaborators report ... Trichinella spiralis , which provide potential targets for new ...
Cached Biology News:Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4Reprogrammed stem cells hit a roadblock 2Trichinosis parasite gets DNA decoded 2
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: